Skip to main content

Cannabis Auxly Cannabis signs funding deal with tobacco giant Imperial Brands

Part of cannabis and investing

Imperial Brands is the latest multinational company to step into the Canadian pot industry, signing a $123-million investment deal with Auxly Cannabis Group that includes a research and development partnership and gives the Vancouver-headquartered firm the global licences to the British tobacco giant’s vaping technology.

The deal announced Thursday would give London-based Imperial Brands a 19.9 per cent stake through a debenture convertible into Auxly equity, with a conversion price of 81 cents per share.

That is 11 per cent higher than Auxly’s share price of 73 cents on the TSX Venture Exchange on Wednesday. Shares of Auxly, which has a portfolio of cannabis brands and products, soared as much as 22 per cent on Thursday to 89 cents apiece.

Story continues below advertisement

“The strategic partnership really enhances our ability to execute on our business strategy and accelerates our growth plan,” Auxly’s president Hugo Alves said in an interview.

“So we are taking in a significant capital injection at a premium to our share price in a difficult market.”

The additional capital will fuel Auxly’s plans to roll out next-generation cannabis products, such as vaporizers, when legalized in Canada later this year, Alves added.

Imperial, whose tobacco brands include Winston and Davidoff cigarettes, has increasingly been focused on e-cigarettes and vaporizers, which are seen as a safer alternative to smoking, amid a shift in consumer preferences.

Imperial’s chief development officer Matthew Phillips said diversifying its portfolio with this investment in Auxly provides the tobacco company with further options for future growth, and builds on last year’s investment in Oxford Cannabinoid Technologies.

“Auxly’s unique assets and capabilities, including strong science and product development credentials, make it an ideal partner for Imperial in the legal Canadian cannabis market,” he said in a news release.

Imperial will have the right to convert the debt into stock at any time during a three-year period.

Story continues below advertisement

If, at the end of the term Imperial has not converted, the debenture will be repayable in full.

In addition to the funds and technology licences, Auxly will get access to Imperial’s Nerudia vapour innovation business and become Imperial’s exclusive global partner for future cannabis products.

In return, the British tobacco firm will designate one out of the five directors on Auxly’s board plus one non-voting observer. As well, the chair of Imperial’s product stewardship and health group will sit on Auxly’s safety board.

The deal is expected to close in the third quarter, subject to approval from the TSX Venture Exchange.

Imperial is the latest consumer goods company to make its foray into pot, in a bid to diversify their offerings as consumer and political winds shift toward a growing acceptance of cannabis use.

In December, Marlboro maker Altria Group Inc. announced a $2.4 billion investment in Canadian cannabis producer Cronos Group Inc. to acquire a 45 per cent ownership stake, and the option to up its stake later to 55 per cent.

Story continues below advertisement

And last year, Nanaimo, B.C.-based cannabis company Tilray Inc. struck an agreement to collaborate with Sandoz AG, part of the Novartis pharmaceutical Group, on medical pot products.

Alcohol giant Constellation Brands last year upped its initial $245 million investment in Canopy Growth Corp. by an additional $5 billion, giving it a 38 per cent stake in the Smiths Falls, Ont.-based cannabis company.

Auxly’s chairman and chief executive Chuck Rifici co-founded Tweed Inc., which later became Canopy.

Ryan Tomkins, an analyst with Jefferies, said the Imperial-Auxly deal was a positive one.

“Although the move is relatively small, we view it as sensible,” he said in a note to clients. “IMB gets possible 20 per cent ownership of a Canadian (licensed producer) in a rapidly growing sector at a good price.”

Alves said the deal with Imperial was the culmination of roughly five and a half months of discussions.

Story continues below advertisement

The transaction comes at a tumultuous time for the cannabis industry as a high-profile scandal rocks the nascent sector.

Licensed cannabis producer CannTrust Holdings Inc. is under investigation by Health Canada, which says it discovered during a recent inspection of its Ontario greenhouse that the company was illegally cultivating cannabis. Its shares on the Toronto Stock Exchange have lost roughly half their value since CannTrust disclosed Health Canada’s findings on July 8.

Also earlier this month, Canopy’s board of directors ousted co-founder Bruce Linton from his role as co-chief executive, days after Constellation Brands’ had expressed dissatisfaction with the cannabis company’s latest earnings.

Last week, Toronto-based licensed producer The Flowr Corporation withdrew its plans to list on the Nasdaq, citing “prevailing market conditions.”

Alves said the CannTrust probe did not impact Auxly’s negotiations with Imperial, which did “very extensive due diligence,” he added.

“It wasn’t an issue in our transaction... a big portion of our founding team are regulatory experts.”

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter